نقطة النهاية البديلة (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "نقطة النهاية البديلة" in Arabic language version.

refsWebsite

Global rank Arabic rank

12doi.org

2^nd place

5^th place

8nih.gov

4^th place

6^th place

2web.archive.org

1^st place

2archive.org

6^th place

3^rd place

1issn.org

57^th place

1,629^th place

1crmagazine.org

low place

1bmj.com

1,226^th place

531^st place

archive.org

Prentice، Ross L. (1989). "Surrogate endpoints in clinical trials: Definition and operational criteria". Statistics in Medicine. ج. 8 ع. 4: 431–440. DOI:10.1002/sim.4780080407.
Horton, Richard (25 أكتوبر 2003). "The statin wars: why AstraZeneca must retreat". Lancet. ج. 362 ع. 9393: 1341. DOI:10.1016/S0140-6736(03)14669-7. PMID:14585629.McKillop T (1 نوفمبر 2003). "The statin wars". Lancet. ج. 362 ع. 9394: 1498. DOI:10.1016/S0140-6736(03)14698-3. PMID:14602449.

bmj.com

Lenzer، J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. ج. 343: d4244. DOI:10.1136/bmj.d4244. PMID:21729988. مؤرشف من الأصل في 2020-01-21.

crmagazine.org

Alexandra Goho, "An Imperfect Substitute" CR Magazine, Spring 2009 2009/Pages/AnImperfectSubstitute.aspx نسخة محفوظة 2018-09-20 على موقع واي باك مشين.

doi.org

De Gruttola، Victor G؛ Clax، Pamela؛ DeMets، David L؛ Downing، Gregory J؛ Ellenberg، Susan S؛ Friedman، Lawrence؛ Gail، Mitchell H؛ Prentice، Ross؛ Wittes، Janet؛ Zeger، Scott L (2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. ج. 22 ع. 5: 485–502. DOI:10.1016/S0197-2456(01)00153-2. ISSN:0197-2456.
Cohn JN (2004). "Introduction to Surrogate Markers". Circulation. ج. 109 ع. 25 Suppl 1: IV20–1. DOI:10.1161/01.CIR.0000133441.05780.1d. PMID:15226247.
Fleming، Thomas R. (1996). "Surrogate End Points in Clinical Trials: Are We Being Misled?". Annals of Internal Medicine. ج. 125 ع. 7: 605. DOI:10.7326/0003-4819-125-7-199610010-00011.
Prentice، Ross L. (1989). "Surrogate endpoints in clinical trials: Definition and operational criteria". Statistics in Medicine. ج. 8 ع. 4: 431–440. DOI:10.1002/sim.4780080407.
O'Quigley، John؛ Flandre، Philippe (مارس 2006). "Quantification of the Prentice Criteria for Surrogate Endpoints". Biometrics. ج. 62 ع. 1: 297–300. DOI:10.1111/j.1541-0420.2006.00538.x.
Sobel، Burton E.؛ Furberg، Curt D. (1997). "Surrogates, Semantics, and Sensible Public Policy". Circulation. ج. 95 ع. 6: 1661–1663. DOI:10.1161/01.CIR.95.6.1661.
Pedersen TR، Olsson AG، Faergeman O، وآخرون (1998). "Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)". Circulation. ج. 97 ع. 15: 1453–1460. DOI:10.1161/01.cir.97.15.1453. PMID:9576425.
Horton, Richard (25 أكتوبر 2003). "The statin wars: why AstraZeneca must retreat". Lancet. ج. 362 ع. 9393: 1341. DOI:10.1016/S0140-6736(03)14669-7. PMID:14585629.McKillop T (1 نوفمبر 2003). "The statin wars". Lancet. ج. 362 ع. 9394: 1498. DOI:10.1016/S0140-6736(03)14698-3. PMID:14602449.
d'Agostino، Ralph B. (2011). "Changing End Points in Breast-Cancer Drug Approval — The Avastin Story". NEJM. ج. 365 ع. 2: e2. DOI:10.1056/NEJMp1106984. PMID:21707384.
Lenzer، J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. ج. 343: d4244. DOI:10.1136/bmj.d4244. PMID:21729988. مؤرشف من الأصل في 2020-01-21.
Hall PS، Lord SR، Collinson M، Marshall H، Jones M، Lowe C، Howard H، Swinson D، Velikova G، Anthoney A، Roy R، Seymour M (2017). "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)". British Journal of Cancer. ج. 116 ع. 4: 472–478. DOI:10.1038/bjc.2016.442. PMC:5318975. PMID:28095397.
Psaty BM، Weiss NS، Furberg CD، وآخرون (1999). "Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease". JAMA. ج. 282 ع. 8: 786–790. DOI:10.1001/jama.282.8.786. PMID:10463718.

issn.org

portal.issn.org

De Gruttola، Victor G؛ Clax، Pamela؛ DeMets، David L؛ Downing، Gregory J؛ Ellenberg، Susan S؛ Friedman، Lawrence؛ Gail، Mitchell H؛ Prentice، Ross؛ Wittes، Janet؛ Zeger، Scott L (2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. ج. 22 ع. 5: 485–502. DOI:10.1016/S0197-2456(01)00153-2. ISSN:0197-2456.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohn JN (2004). "Introduction to Surrogate Markers". Circulation. ج. 109 ع. 25 Suppl 1: IV20–1. DOI:10.1161/01.CIR.0000133441.05780.1d. PMID:15226247.
Pedersen TR، Olsson AG، Faergeman O، وآخرون (1998). "Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)". Circulation. ج. 97 ع. 15: 1453–1460. DOI:10.1161/01.cir.97.15.1453. PMID:9576425.
Horton, Richard (25 أكتوبر 2003). "The statin wars: why AstraZeneca must retreat". Lancet. ج. 362 ع. 9393: 1341. DOI:10.1016/S0140-6736(03)14669-7. PMID:14585629.McKillop T (1 نوفمبر 2003). "The statin wars". Lancet. ج. 362 ع. 9394: 1498. DOI:10.1016/S0140-6736(03)14698-3. PMID:14602449.
d'Agostino، Ralph B. (2011). "Changing End Points in Breast-Cancer Drug Approval — The Avastin Story". NEJM. ج. 365 ع. 2: e2. DOI:10.1056/NEJMp1106984. PMID:21707384.
Lenzer، J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. ج. 343: d4244. DOI:10.1136/bmj.d4244. PMID:21729988. مؤرشف من الأصل في 2020-01-21.
Hall PS، Lord SR، Collinson M، Marshall H، Jones M، Lowe C، Howard H، Swinson D، Velikova G، Anthoney A، Roy R، Seymour M (2017). "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)". British Journal of Cancer. ج. 116 ع. 4: 472–478. DOI:10.1038/bjc.2016.442. PMC:5318975. PMID:28095397.
Psaty BM، Weiss NS، Furberg CD، وآخرون (1999). "Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease". JAMA. ج. 282 ع. 8: 786–790. DOI:10.1001/jama.282.8.786. PMID:10463718.

ncbi.nlm.nih.gov

Hall PS، Lord SR، Collinson M، Marshall H، Jones M، Lowe C، Howard H، Swinson D، Velikova G، Anthoney A، Roy R، Seymour M (2017). "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)". British Journal of Cancer. ج. 116 ع. 4: 472–478. DOI:10.1038/bjc.2016.442. PMC:5318975. PMID:28095397.

web.archive.org

Alexandra Goho, "An Imperfect Substitute" CR Magazine, Spring 2009 2009/Pages/AnImperfectSubstitute.aspx نسخة محفوظة 2018-09-20 على موقع واي باك مشين.
Lenzer، J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. ج. 343: d4244. DOI:10.1136/bmj.d4244. PMID:21729988. مؤرشف من الأصل في 2020-01-21.